Chronic necrotizing pulmonary aspergillosis in a patient treated with a tumor necrosis factor-α inhibitor

International Journal of Rheumatic Diseases

Volumn 13, Issue 3, 2010, Pages

  Lee, Eun Jung ^a   Song, Ran ^a   Park, Ji Na ^a   Lee, Yeon Ah ^a   Son, Jun Seong ^a   Hong, Seung Jae ^a   Yang, Hyung In ^a   Lee, Sang Hoon ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

Ankylosing spondylitis; Chronic necrotizing pulmonary aspergillosis; Etanercept; Tumor necrosis factor alpha

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; FUNGUS ANTIBODY; FUNGUS ANTIGEN; ITRACONAZOLE; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABNORMAL RESPIRATORY SOUND; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CASE REPORT; CHRONIC DISEASE; CHRONIC NECROTIZING PULMONARY ASPERGILLOSIS; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CROHN DISEASE; DRUG WITHDRAWAL; FEVER; FUNGUS BALL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION TEST; LEUKOCYTOSIS; LIVER FUNCTION TEST; LUNG ASPERGILLOSIS; LUNG CAVITY; LUNG LESION; LUNG LOBE; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RHEUMATOID ARTHRITIS; THORAX RADIOGRAPHY; TUBERCULOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFUNGAL AGENTS; HUMANS; IMMUNOGLOBULIN G; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955408431     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2010.01528.x     Document Type: Article

References (13)

1. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003, 48:3013-22.
2. Yun HR, Kim TJ, Kim TH, Choi HS, Bae SC. Anti-TNF-alpha therapy in rheumatic diseases with chronic hepatitis B virus infection. J Korean Rheum Assoc 2007, 24:242-50.
3. Safety update on TNF-α antagonists: infliximab and etanercept. Food and Drug Administration, Center for Biologics Evaluation and Research. 2001, Arthritis Advisory Committee Meeting, August 17, 2001
4. Rychly DJ, Di Piro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005, 25:1181-92.
5. Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 2002, 103:13-21.
6. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008, 83:181-94.
7. Mambula SS, Sau K, Henneke P, Golenbock DT, Levitz SM. Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem 2002, 277:39320-6.
8. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005, 41:S199-203.
9. Shen C, Assche GV, Colpaert S. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005, 21:251-8.
10. Cunnane G, Doran M, Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003, 17:345-63.
11. Binder RE, Faling LJ, Pugatch RD. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine 1982, 61:109-24.
12. Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest 2002, 121:1988-99.
13. Sugar AM, Olek EA. Aspergillus syndrome, mucormycosis and pulmonary candidiasis. Fisherman's Pulmonary Disease and Disorders 1998, 2. Fishman AP, ed, 2nd edn, p, McGraw-Hill, New York